| abstract |
The present invention relates to compounds C having the structure of formula 1: where n is an integrator from 1 to 5; R1 is optionally substituted alkyl, alkenyl, cycloalkyl, aryl, hetericyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkylinyloxy; R2 is alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5-NHC (= Y) R4, -NHC (= Y) NR5, Rx, -NHC (= O) OR4-NHS02R4, C (= Y) NR4R5, C (= O) OR6 [where Y is oxygen or sulfide], OR5-O (C = O) NR4R5, O-Acyl, S (O) mR4, -SO2N (R4) 2, cyano, amidino or guanidino [Where R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl, or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cloclyalkyalkyl, or aralkyl; A is OH, OR4, -OC (= O) NR4R5, O-acyl, NH2, NR4R5, -NHC (= Y) R4, -NHC (= Y) NR5Rx, -NHC (= O) OR4, -NHSO2R4, and for processes of its synthesis. This invention is also related to pharmacological compositions containing compounds of the present invention, and method for treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, soriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory disorder syndrome, periodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which can lead to ischemic heart failure and restenosis, cardiac arrest, kidney disease, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase. |